BPC-157/TB-500 Blend Dosage, Reconstitution & Mixing Trends

Explore bpc-157/tb-500 blend calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.

Anonymized bpc-157/tb-500 blend calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.

What BPC-157/TB-500 Blend Is

This blend pairs BPC-157 and TB-500, two tissue-repair peptides, and is one of the most-sourced research blends for soft-tissue and recovery protocols. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.[1][2]

BPC-157 acts on the VEGF–NO pathway and modulates growth-hormone-receptor expression in fibroblasts, while TB-500 sequesters G-actin and promotes endothelial-cell migration, angiogenesis, and stem-cell mobilization. The two molecules engage distinct repair mechanisms, which is the rationale behind their combination in research protocols.

No published trials evaluate the fixed-ratio combination. Individual evidence draws from the Sikiric group on BPC-157 (>200 animal studies)[1] and the Goldstein/RegeneRx work on thymosin beta-4 in dermal wound healing, dry-eye disease, and post-MI cardiac repair.[2] Both molecules appear on the FDA 503A "do not compound" interest list.

Neither component is FDA-approved. Both appear on the FDA 503A Category 2 bulks list (Sep 2023). Research-only material.

BPC-157/TB-500 Blend Research Sources

BPC-157/TB-500 Blend Dosing Context

BPC-157/TB-500 Blend has a reported half-life of ~2 days (TB-500-driven). The pharmacokinetic reference models an interval of weekly (or split into 2 doses); this is not a measured community cadence or a dosing recommendation. TB-500 carries the buildup story here; BPC-157 clears quickly and BPC tone depends on dosing frequency. Splitting the weekly dose into two injections keeps both components more stable. Pharmacokinetic source: Pre-clinical estimates for each component. BPC-157/TB-500 Blend is a blend of BPC-157 and TB-500, so a reconstitution figure for it covers the combined vial contents rather than any single component. It is catalogued under Recovery Peptides on WPA.

BPC-157/TB-500 Blend Community Calculator Data

5,747 BPC-157/TB-500 Blend reconstitution calculations have been logged by the WPA community.

This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.

These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.

WPA Analysis

BPC-157/TB-500 Blend Research Background and Calculator Data

The BPC-157/TB-500 blend is a deliberate two-peptide pairing that brings together the two most-researched healing peptides in the modern marketplace. The rationale traces to two separate preclinical bodies of work that converged in the early 2010s. BPC-157 — the Body Protection Compound pentadecapeptide — comes from the Sikiric et al. program at the University of Zagreb, which produced more than 200 published rodent and dog studies on its effects in gastric ulcer protection, tendon-to-bone healing, ligament repair, and accelerated wound closure. TB-500 is a synthetic 17-amino-acid fragment of thymosin beta-4, the actin-sequestering peptide first characterized in the Goldstein et al. body of work through the 1980s and 1990s, with downstream wound-healing and corneal-repair literature that fed an FDA orphan-drug designation for thymosin beta-4 in epidermolysis bullosa and a Phase II program (RegeneRx's RGN-259 in dry eye disease) that did not advance to a labeled indication. The blend pairs the two on the hypothesis that they target different stages of the repair process: BPC-157 is described in the Sikiric work as acting on the early angiogenesis and granulation-tissue phase, while thymosin beta-4 is implicated in the actin-cytoskeleton-driven cell migration phase that follows. The combination has never been formally trialed — there is no published controlled human study of the blend at any dose — and the protocol layer is built entirely on extrapolation from the two molecules' separate rodent literatures.

The combination has no approved human indication anywhere in the world, and yet it has become one of the most widely discussed dual-peptide protocols across biohacking, longevity, fitness, and progressive clinical circles. The reason is not regulatory — it is practical and biological. Both compounds are closely derived from sequences already present in human physiology: BPC-157 is a fragment of a Body Protection Compound originally isolated from human gastric juice, while TB-500 is a synthetic version of the active region of thymosin beta-4 — a peptide naturally found in high concentrations throughout human tissue, particularly in the thymus and blood platelets. Because the body already produces and manages both parent sequences, the community's working hypothesis has consistently been that the side-effect ceiling is low. That hypothesis is increasingly being tested in the open: forward-thinking physicians, longevity clinicians, and thorough self-experimenters are running before-and-after bloodwork and sharing the results publicly, and the pattern that has emerged across those informal reports is one of the cleanest adverse-event profiles in the peptide research space — minimal off-target hormone disruption, no identified lethal dose in the rodent literature, and no serious adverse event signal across the practitioner-reported use cases that have accumulated publicly. That profile — potent enough to generate consistent recovery reports, benign enough to attract practitioners who otherwise would not touch unapproved compounds — is why this stack's momentum spans communities that rarely agree: the competitive-sports community chasing injury turnaround, the longevity community targeting systemic inflammation and tissue maintenance, and the clinical fringe of practitioners who view it as a research-supported recovery adjunct. WPA expects this trend to accelerate as the combination continues to accumulate community and practitioner attention. What WPA uniquely provides in this environment is something no forum thread, fitness influencer post, or individual practitioner report can offer: hundreds of anonymized data points from real researchers, aggregated without bias or commercial interest. Every Reddit comment, influencer recommendation, or clinic protocol is a sample size of one.

Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.

WPA DOSING INSIGHT

Dose and Frequency Calculator Inputs

The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.

WPA RECONSTITUTION INSIGHT

Vial Size and BAC Water Calculator Inputs

Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.

These figures come from anonymized WPA peptide calculator sessions.

All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.